For some individuals, microdosing may optimize the therapeutic effects while minimizing side effects, leading to better overall management of conditions like type 2 diabetes or obesity. While still requiring careful monitoring, microdosing may help reduce overall costs by allowing individuals to utilize lower amounts of the medication effectively.

Microdosing GLP-1 medications, which involves taking lower doses than typically prescribed, can offer several potential benefits to the client. Lower doses may reduce the risk of side effects such as nausea, vomiting, and gastrointestinal discomfort, making it easier for individuals to tolerate the medication. Microdosing allows the body to gradually adjust to the medication, potentially enhancing its efficacy over time and minimizing adverse reactions.

At WLHH we will often start clients at 25% of the normal 0.25mg dose of semaglutide recommended by the manufacturer. The half-life of semaglutide is 1 week and peak plasma levels occur in 1-3 days after injection. Based on these pharmacokinetics we will also alternate a higher dose and lower dose every other week to keep side effects at a minimum. We have also split a dose of the medication so that half the dose is taken at the beginning of the week and the other half is taken in the middle of the week.